Home > Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.

Schoeler, Tabea and Ferris, Jason and Winstock, Adam R (2022) Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis. Translational Psychiatry, 12, 369. doi: 10.1038/s41398-022-02112-8.

External website: https://www.nature.com/articles/s41398-022-02112-8

Cannabis, a widely used psychoactive substance, can trigger acute cannabis-associated psychotic symptoms (CAPS) in people who use cannabis (PWUC). To assess rates and correlates of CAPS requiring emergency medical treatment, we analyzed data from an international sample of PWUC (n = 233,475). We found that 0.47% PWUC reported lifetime occurrence of CAPS, defined as the occurrence of hallucinations and/or paranoia requiring emergency medical treatment following the use of cannabis. A range of factors correlated with risk of CAPS in the last year: higher rates were observed in young individuals and those residing in Denmark. Furthermore, risk was elevated in those using predominantly high-potency resin, those mixing cannabis with tobacco and those with a diagnosis of psychosis, bipolar, anxiety and depression, compared to individuals without a mental health diagnosis. Taken together, acute self-limiting psychotic symptoms in the context of cannabis use may occur in about 1 in 200 PWUC's lifetime. Some individuals could be particularly sensitive to the adverse psychological effects of cannabis, such as young individuals or those with pre-existing mental health vulnerabilities. In light of the movements towards legalization of recreational cannabis, more research should focus on the potential harms related to cannabis use, to educate PWUC and the public about risks related to its use.


Repository Staff Only: item control page